Lactobacillus rhamnosus LRa05 on glycemic control and gut microbiota in patients with type 2 diabetes.

IF 4.6 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

World Journal of Diabetes Pub Date : 2025-07-15 DOI:10.4239/wjd.v16.i7.106821

Lin Geng, Ting-Ting Sun, Wen-Bo Xia, Yin Qin, Di Huo, Guang-Jing Qu

{"title":"Lactobacillus rhamnosus LRa05 on glycemic control and gut microbiota in patients with type 2 diabetes.","authors":"Lin Geng, Ting-Ting Sun, Wen-Bo Xia, Yin Qin, Di Huo, Guang-Jing Qu","doi":"10.4239/wjd.v16.i7.106821","DOIUrl":null,"url":null,"abstract":"Background: Type 2 diabetes mellitus (T2DM) is a metabolic disorder linked to high blood glucose and gut dysbiosis. Probiotics like Lactobacillus rhamnosus LRa05 may improve glycemic control and gut microbiota.Aim: To explore the impact of LRa05 with hypoglycemic medications on glycemic control and intestinal flora in T2DM patients with gut dysbiosis.Methods: Seventy-six participants were randomly assigned to receive either LRa05 (0.1 g 2 × 1010 CFU) (n = 38) or a placebo (n = 38) for 12 weeks. Baseline characteristics were recorded, and changes in glycated hemoglobin, fasting blood glucose, and other biochemical indices were assessed using repeated measures one-way analysis of variance. Additionally, gut microbiota diversity was analyzed through species accumulation and alpha and beta diversity metrics.Results: The intervention group showed statistically significant improvements in lipid profiles, particularly in high-density lipoprotein cholesterol levels, which increased significantly over time (P < 0.001). Additionally, fasting blood glucose was significantly reduced in the LRa05 group compared with the placebo group (P < 0.001). No significant changes were observed in glycated hemoglobin, insulin sensitivity, or systemic inflammatory markers such as C-reactive protein. Furthermore, gut microbiota analysis revealed significant shifts in composition following the intervention, particularly an increase in Bifidobacterium and a decrease in Bacillota, indicating beneficial effects on gut health.Conclusion: This study demonstrated that the combination of Lactobacillus rhamnosus LRa05 and hypoglycemic medications positively impacted glycemic control, specifically reflected in improved levels of high-density lipoprotein and fasting blood glucose. Additionally, significant alterations in gut microbiota composition were observed in patients with T2DM, indicating a potential synergistic effect between gut health and blood glucose regulation.","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 7","pages":"106821"},"PeriodicalIF":4.6000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278088/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v16.i7.106821","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a metabolic disorder linked to high blood glucose and gut dysbiosis. Probiotics like Lactobacillus rhamnosus LRa05 may improve glycemic control and gut microbiota.

Aim: To explore the impact of LRa05 with hypoglycemic medications on glycemic control and intestinal flora in T2DM patients with gut dysbiosis.

Methods: Seventy-six participants were randomly assigned to receive either LRa05 (0.1 g 2 × 10¹⁰ CFU) (n = 38) or a placebo (n = 38) for 12 weeks. Baseline characteristics were recorded, and changes in glycated hemoglobin, fasting blood glucose, and other biochemical indices were assessed using repeated measures one-way analysis of variance. Additionally, gut microbiota diversity was analyzed through species accumulation and alpha and beta diversity metrics.

Results: The intervention group showed statistically significant improvements in lipid profiles, particularly in high-density lipoprotein cholesterol levels, which increased significantly over time (P < 0.001). Additionally, fasting blood glucose was significantly reduced in the LRa05 group compared with the placebo group (P < 0.001). No significant changes were observed in glycated hemoglobin, insulin sensitivity, or systemic inflammatory markers such as C-reactive protein. Furthermore, gut microbiota analysis revealed significant shifts in composition following the intervention, particularly an increase in Bifidobacterium and a decrease in Bacillota, indicating beneficial effects on gut health.

Conclusion: This study demonstrated that the combination of Lactobacillus rhamnosus LRa05 and hypoglycemic medications positively impacted glycemic control, specifically reflected in improved levels of high-density lipoprotein and fasting blood glucose. Additionally, significant alterations in gut microbiota composition were observed in patients with T2DM, indicating a potential synergistic effect between gut health and blood glucose regulation.

查看原文本刊更多论文

鼠李糖乳杆菌LRa05对2型糖尿病患者血糖控制和肠道菌群的影响。

背景：2型糖尿病（T2DM）是一种与高血糖和肠道生态失调相关的代谢紊乱。像鼠李糖乳杆菌LRa05这样的益生菌可以改善血糖控制和肠道微生物群。目的：探讨LRa05联合降糖药物对2型糖尿病合并肠道生态失调患者血糖控制及肠道菌群的影响。方法：76名参与者被随机分配接受LRa05 (0.1 g 2 × 1010 CFU) （n = 38）或安慰剂（n = 38）治疗12周。记录基线特征，使用重复测量单因素方差分析评估糖化血红蛋白、空腹血糖和其他生化指标的变化。此外，通过物种积累和α和β多样性指标分析肠道微生物群多样性。结果：干预组在脂质谱方面有统计学上的显著改善，特别是高密度脂蛋白胆固醇水平，随着时间的推移显著增加（P < 0.001）。此外，与安慰剂组相比，LRa05组的空腹血糖显著降低（P < 0.001）。在糖化血红蛋白、胰岛素敏感性或全身炎症标志物（如c反应蛋白）方面未观察到显著变化。此外，肠道菌群分析显示，干预后肠道菌群的组成发生了显著变化，特别是双歧杆菌的增加和杆菌的减少，表明对肠道健康有益。结论：本研究表明鼠李糖乳杆菌LRa05与降糖药物联合使用对血糖控制有积极影响，具体表现在改善高密度脂蛋白和空腹血糖水平。此外，在T2DM患者中观察到肠道微生物群组成的显著改变，表明肠道健康和血糖调节之间存在潜在的协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

自引率

2.40%

发文量

909

期刊介绍： The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.